Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GILEAD SCIENCES, INC.GILD · Entity 405 | Director | March 28, 2024 | March 29, 2024 |
| Medtronic plcMDT · Entity 2888 | Director | April 27, 2026 | April 29, 2026 |
| MiniMed Group, Inc.MMED · Entity 3758 | Director | October 09, 2026 | October 13, 2026 |
| NEW RITE AID, LLCRAD · Entity 87704 | Director | July 07, 2021 | July 09, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GILEAD SCIENCES, INC.
Report date March 28, 2024 · Filed March 29, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 3,258.1388 |
Reported balance
After 2024-03-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-03-28 · Grant · Acquired 33.8931 · Balance 3,258.1388 F1: Each share of phantom stock is the economic equivalent of one share of Gilead common stock. F2: Phantom shares accrued under dividend equivalent rights, which are settled in shares and distributed with the phantom stock units to which they relate. F3: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of phantom stock is the economic equivalent of one share of Gilead common stock.
F2: Phantom shares accrued under dividend equivalent rights, which are settled in shares and distributed with the phantom stock units to which they relate.
F3: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person.
Medtronic plc
Report date April 27, 2026 · Filed April 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 10,347 |
Reported balance
After 2026-04-27 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-04-27 · Grant · Acquired 2,111 · Balance 10,347 F1: Represents an award of restricted stock units that vest on the one-year anniversary of the award date. F2: Includes 65 shares acquired through dividend reinvestment since the last report filed by the reporting person. |
| Ordinary SharesSEC Table I · non-derivative | Direct | 10,140 |
Reported balance
After 2026-04-28 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-04-28 · Tax withholding · Disposed 207 · Balance 10,140 F3: Represents shares withheld for payment of taxes upon the vesting of restricted stock units previously reported on Table I. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of restricted stock units that vest on the one-year anniversary of the award date.
F2: Includes 65 shares acquired through dividend reinvestment since the last report filed by the reporting person.
F3: Represents shares withheld for payment of taxes upon the vesting of restricted stock units previously reported on Table I.
MiniMed Group, Inc.
Report date October 09, 2026 · Filed October 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 39,573 |
Reported balance
After 2026-10-09 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-10-09 · Grant · Acquired 11,795 · Balance 39,573 F1: Represents the grant of restricted stock units ("RSUs") pursuant to the 2026 MiniMed Group, Inc. Long Term Incentive Plan that vest on the one-year anniversary of the grant date. F2: Includes shares of common stock to be issued in connection with the vesting of one or more RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the grant of restricted stock units ("RSUs") pursuant to the 2026 MiniMed Group, Inc. Long Term Incentive Plan that vest on the one-year anniversary of the grant date.
F2: Includes shares of common stock to be issued in connection with the vesting of one or more RSUs.
NEW RITE AID, LLC
Report date July 07, 2021 · Filed July 09, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 45,943 |
Reported balance
After 2021-07-07 transaction · row 1
1 source rowRow 1 · 2021-07-07 · Grant · Acquired 10,617 · Balance 45,943 F1: Grant of restricted stock exempt from Section 16(b) under Rule 16b-(3)(d). |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 250 |
Reported balance
Holding disclosure · report date 2021-07-07 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 250 |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted stock exempt from Section 16(b) under Rule 16b-(3)(d).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 09, 2026 Filed Oct 13, 2026 22:13 UTC | MiniMed Group, Inc. MMED · Entity 3758 | GrantCommon Stock | 11,795 | $0.00 | $0.00 |
DisclosureSEC source: 0001468818-26-000004 · wk-form4_1791929588.xml · nonDerivative · entry 1 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,573 F1 · shares: Represents the grant of restricted stock units ("RSUs") pursuant to the 2026 MiniMed Group, Inc. Long Term Incentive Plan that vest on the one-year anniversary of the grant date. F2 · balance_after: Includes shares of common stock to be issued in connection with the vesting of one or more RSUs. Read SEC document |
| April 28, 2026 Filed Apr 29, 2026 20:16 UTC | Medtronic plc MDT · Entity 2888 | Tax withholdingOrdinary Shares | 207 | $81.90 | $16,953.30 |
DisclosureSEC source: 0001468818-26-000002 · wk-form4_1777493804.xml · nonDerivative · entry 2 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,140 F3 · shares: Represents shares withheld for payment of taxes upon the vesting of restricted stock units previously reported on Table I. Read SEC document |
| April 27, 2026 Filed Apr 29, 2026 20:16 UTC | Medtronic plc MDT · Entity 2888 | GrantOrdinary Shares | 2,111 | $0.00 | $0.00 |
DisclosureSEC source: 0001468818-26-000002 · wk-form4_1777493804.xml · nonDerivative · entry 1 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,347 F1 · shares: Represents an award of restricted stock units that vest on the one-year anniversary of the award date. F2 · balance_after: Includes 65 shares acquired through dividend reinvestment since the last report filed by the reporting person. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 20:31 UTC | MiniMed Group, Inc. MMED · Entity 3758 | GrantCommon Stock | 27,778 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-016854 · wk-form4_1773261060.xml · nonDerivative · entry 1 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,778 F1 · shares: Represents restricted stock units that vest on the one-year anniversary of the grant date. F2 · balance_after: Includes shares to be issued in connection with the vesting of one or more restricted stock units. Read SEC document |
| April 29, 2025 Filed Apr 30, 2025 20:19 UTC | Medtronic plc MDT · Entity 2888 | Tax withholdingOrdinary Shares | 216 | $84.60 | $18,273.60 |
DisclosureSEC source: 0001613103-25-000068 · wk-form4_1746044332.xml · nonDerivative · entry 2 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,171 F3 · shares: Represents shares withheld for payment of taxes upon the vesting of restricted stock units previously reported on Table I. Read SEC document |
| April 28, 2025 Filed Apr 30, 2025 20:19 UTC | Medtronic plc MDT · Entity 2888 | GrantOrdinary Shares | 2,083 | $84.04 | $175,055.32 |
DisclosureSEC source: 0001613103-25-000068 · wk-form4_1746044332.xml · nonDerivative · entry 1 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,387 F1 · shares: Represents an award of restricted stock units that vest on the one-year anniversary of the award date. F2 · balance_after: Includes 74 shares acquired through dividend reinvestment since the last report filed by the reporting person. Read SEC document |
| May 01, 2024 Filed May 3, 2024 17:10 UTC | Medtronic plc MDT · Entity 2888 | Tax withholdingOrdinary Shares | 192 | $80.89 | $15,530.88 |
DisclosureSEC source: 0001613103-24-000051 · wk-form4_1714756207.xml · nonDerivative · entry 1 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,230 F1 · shares: Represents shares withheld for payment of taxes upon the vesting of restricted stock units previously reported on Table I. Read SEC document |
| April 29, 2024 Filed May 1, 2024 21:14 UTC | Medtronic plc MDT · Entity 2888 | GrantOrdinary Shares | 2,165 | $80.86 | $175,061.90 |
DisclosureSEC source: 0001613103-24-000033 · wk-form4_1714598084.xml · nonDerivative · entry 1 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,422 F1 · shares: Represents an award of restricted stock units that vest on the one-year anniversary of the award date. F2 · balance_after: Includes 66 shares acquired through dividend reinvestment since the last report filed by the reporting person. Read SEC document |
| March 28, 2024 Filed Mar 29, 2024 21:19 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantPhantom Stock · Derivative | 33.8931 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-011458 · form4.xml · derivative · entry 1 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,258.1388 Underlying: Common Stock · 33.8931 shares Expires not disclosed F1 · security: Each share of phantom stock is the economic equivalent of one share of Gilead common stock. F2 · shares: Phantom shares accrued under dividend equivalent rights, which are settled in shares and distributed with the phantom stock units to which they relate. F3 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. F3 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. Read SEC document |
| December 28, 2023 Filed Dec 29, 2023 21:36 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantPhantom Stock · Derivative | 29.5297 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-030570 · form4.xml · derivative · entry 1 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,224.2457 Underlying: Common Stock · 29.5297 shares Expires not disclosed F1 · security: Each share of phantom stock is the economic equivalent of one share of Gilead common stock. F2 · shares: Phantom shares accrued under dividend equivalent rights, which are settled in shares and distributed with the phantom stock units to which they relate. F3 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. F3 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. Read SEC document |
| September 28, 2023 Filed Sep 30, 2023 00:09 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantPhantom Stock · Derivative | 31.4564 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-024892 · form4.xml · derivative · entry 1 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,194.7161 Underlying: Common Stock · 31.4564 shares Expires not disclosed F1 · security: Each share of phantom stock is the economic equivalent of one share of Gilead common stock. F2 · shares: Phantom shares accrued under dividend equivalent rights, which are settled in shares and distributed with the phantom stock units to which they relate. F3 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. F3 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. Read SEC document |
| June 29, 2023 Filed Jun 30, 2023 19:54 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantPhantom Stock · Derivative | 30.9073 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-019607 · form4.xml · derivative · entry 1 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,163.2596 Underlying: Common Stock · 30.9073 shares Expires not disclosed F1 · security: Each share of phantom stock is the economic equivalent of one share of Gilead common stock. F2 · shares: Phantom shares accrued under dividend equivalent rights, which are settled in shares and distributed with the phantom stock units to which they relate. F3 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. F3 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. Read SEC document |
| May 03, 2023 Filed May 4, 2023 21:57 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 10,173 | $79.45 Strike: $79.45 | $808,244.85 |
DisclosureSEC source: 0001127602-23-014554 · form4.xml · derivative · entry 2 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,173 Underlying: Common Stock · 10,173 shares Expires 2033-05-03 F3 · derivative.exercise_date: 100% of the shares subject to the stock option vested immediately upon the grant date of May 3, 2023. Read SEC document |
| May 03, 2023 Filed May 4, 2023 21:57 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 1,887 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-014554 · form4.xml · nonDerivative · entry 1 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 92,653 F1 · security: Represents 1,887 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of May 3, 2023. F2 · balance_after: Shares are held in a Revocable Living Trust. F2 · ownership.nature: Shares are held in a Revocable Living Trust. Read SEC document |
| May 02, 2023 Filed May 3, 2023 20:34 UTC | Medtronic plc MDT · Entity 2888 | Tax withholdingOrdinary Shares | 169 | $90.23 | $15,248.87 |
DisclosureSEC source: 0001613103-23-000027 · wf-form4_168314604786031.xml · nonDerivative · entry 2 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,191 F3 · shares: Represents shares withheld for payment of withholding taxes upon the vesting of previously reported restricted stock units. Read SEC document |
| May 01, 2023 Filed May 3, 2023 20:34 UTC | Medtronic plc MDT · Entity 2888 | GrantOrdinary Shares | 1,930 | $90.68 | $175,012.40 |
DisclosureSEC source: 0001613103-23-000027 · wf-form4_168314604786031.xml · nonDerivative · entry 1 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,360 F1 · shares: Represents an award of restricted stock units that vest on the one-year anniversary of the award date. F2 · balance_after: Includes 56 units acquired through dividend reinvestment since the last report filed by the reporting person. Read SEC document |
| May 01, 2023 Filed May 2, 2023 23:12 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GiftCommon Stock | 12,868 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-014140 · form4.xml · nonDerivative · entry 1 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 90,766 F1 · shares: Upon expiration of a Grantor Retained Annuity Trust, 12,868 shares were transferred to beneficiaries on May 1, 2023. F2 · ownership.nature: Shares are held in a Revocable Living Trust. Read SEC document |
| March 30, 2023 Filed Apr 1, 2023 00:29 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantPhantom Stock · Derivative | 28.5799 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-011726 · form4.xml · derivative · entry 1 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,132.3523 Underlying: Common Stock · 28.5799 shares Expires not disclosed F1 · security: Each share of phantom stock is the economic equivalent of one share of Gilead common stock. F2 · shares: Phantom shares accrued under dividend equivalent rights, which are settled in shares and distributed with the phantom stock units to which they relate. F3 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. F3 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. Read SEC document |
| March 09, 2023 Filed Mar 10, 2023 22:23 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 8,442 | $0.00 Strike: $52.38 | $0.00 |
DisclosureSEC source: 0001127602-23-009787 · form4.xml · derivative · entry 3 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,442 shares Expires 2023-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Options vest quarterly over the first year of service upon the earlier of May 8, 2014, or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| March 09, 2023 Filed Mar 10, 2023 22:23 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 8,442 | $52.38 | $442,191.96 |
DisclosureSEC source: 0001127602-23-009787 · form4.xml · nonDerivative · entry 1 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,442 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 29, 2022 Filed Dec 30, 2022 21:35 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantPhantom Stock · Derivative | 26.349 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-028356 · form4.xml · derivative · entry 1 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,103.7725 Underlying: Common Stock · 26.349 shares Expires not disclosed F1 · security: Each share of phantom stock is the economic equivalent of one share of Gilead common stock. F2 · shares: Phantom shares accrued under dividend equivalent rights, which are settled in shares and distributed with the phantom stock units to which they relate. F3 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. F3 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. Read SEC document |
| September 29, 2022 Filed Sep 30, 2022 22:49 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantPhantom Stock · Derivative | 35.2119 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-023127 · form4.xml · derivative · entry 1 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,077.4234 Underlying: Common Stock · 35.2119 shares Expires not disclosed F1 · security: Each share of phantom stock is the economic equivalent of one share of Gilead common stock. F2 · shares: Phantom shares accrued under dividend equivalent rights, which are settled in shares and distributed with the phantom stock units to which they relate. F3 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. F3 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. Read SEC document |
| June 29, 2022 Filed Jun 30, 2022 23:18 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantPhantom Stock · Derivative | 35.1339 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-018309 · form4.xml · derivative · entry 1 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,042.2115 Underlying: Common Stock · 35.1339 shares Expires not disclosed F1 · security: Each share of phantom stock is the economic equivalent of one share of Gilead common stock. F2 · shares: Phantom shares accrued under dividend equivalent rights, which are settled in shares and distributed with the phantom stock units to which they relate. F3 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. F3 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. Read SEC document |
| May 05, 2022 Filed May 6, 2022 22:52 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 15,851 | $0.00 Strike: $61.35 | $0.00 |
DisclosureSEC source: 0001127602-22-013724 · form4.xml · derivative · entry 2 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,851 Underlying: Common Stock · 15,851 shares Expires 2032-05-05 F3 · derivative.exercise_date: 100% of the shares subject to the stock option vested immediately upon the grant date of May 5, 2022. Read SEC document |
| May 05, 2022 Filed May 6, 2022 22:52 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 2,444 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-013724 · form4.xml · nonDerivative · entry 1 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 95,192 F1 · security: Represents 2.444 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of May 5, 2022. F2 · balance_after: Includes 65,874 shares held in a Revocable Living Trust and 29,318 shares held in a Grantor Retained Annuity Trust. F2 · ownership.nature: Includes 65,874 shares held in a Revocable Living Trust and 29,318 shares held in a Grantor Retained Annuity Trust. Read SEC document |
| May 03, 2022 Filed May 4, 2022 22:17 UTC | Medtronic plc MDT · Entity 2888 | Tax withholdingOrdinary Shares | 161 | $103.11 | $16,600.71 |
DisclosureSEC source: 0001127602-22-013315 · form4.xml · nonDerivative · entry 2 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,374 F1 · balance_after: This balance increased by 18 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| May 03, 2022 Filed May 4, 2022 00:07 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 2,223 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-013122 · form4.xml · derivative · entry 2 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,830 Underlying: Common Stock · 2,223 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: 100% of the restricted stock units vested on May 3, 2022. F3 · derivative.expiration_date: 100% of the restricted stock units vested on May 3, 2022. Read SEC document |
| May 03, 2022 Filed May 4, 2022 00:07 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 2,223 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-013122 · form4.xml · nonDerivative · entry 1 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 92,748 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · balance_after: Includes 63,430 shares held in a Revocable Living Trust and 29,318 shares held in a Grantor Retained Annuity Trust. F2 · ownership.nature: Includes 63,430 shares held in a Revocable Living Trust and 29,318 shares held in a Grantor Retained Annuity Trust. Read SEC document |
| May 02, 2022 Filed May 4, 2022 22:17 UTC | Medtronic plc MDT · Entity 2888 | GrantOrdinary Shares | 1,697 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-013315 · form4.xml · nonDerivative · entry 1 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,535 Read SEC document |
| April 28, 2022 Filed Apr 29, 2022 22:43 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 16,322 | $0.00 Strike: $25.63 | $0.00 |
DisclosureSEC source: 0001127602-22-012762 · form4.xml · derivative · entry 2 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,322 shares Expires 2022-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options vested quarterly over the first year of service and were fully vested on May 10, 2013. Read SEC document |
| April 28, 2022 Filed Apr 29, 2022 22:43 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 16,322 | $25.63 | $418,251.25 |
DisclosureSEC source: 0001127602-22-012762 · form4.xml · nonDerivative · entry 1 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 90,525 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 61,207 shares held in a Revocable Living Trust and 29,318 shares held in a Grantor Retained Annuity Trust. F1 · ownership.nature: Includes 61,207 shares held in a Revocable Living Trust and 29,318 shares held in a Grantor Retained Annuity Trust. Read SEC document |
| March 30, 2022 Filed Mar 31, 2022 22:31 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantPhantom Stock · Derivative | 36.3498 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-010760 · form4.xml · derivative · entry 1 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,007.0776 Underlying: Common Stock · 36.3498 shares Expires not disclosed F1 · security: Each share of phantom stock is the economic equivalent of one share of Gilead common stock. F2 · shares: Phantom shares accrued under dividend equivalent rights, which are settled in shares and distributed with the phantom stock units to which they relate. F3 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. F3 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. Read SEC document |
| December 30, 2021 Filed Jan 3, 2022 23:10 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantPhantom Stock · Derivative | 28.476 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-000170 · form4.xml · derivative · entry 1 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,970.7278 Underlying: Common Stock · 28.476 shares Expires not disclosed F1 · security: Each share of phantom stock is the economic equivalent of one share of Gilead common stock. F2 · shares: Phantom shares accrued under dividend equivalent rights, which are settled in shares and distributed with the phantom stock units to which they relate. F3 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. F3 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. Read SEC document |
| September 29, 2021 Filed Oct 1, 2021 20:38 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantPhantom Stock · Derivative | 29.1556 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-026321 · form4.xml · derivative · entry 1 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,942.2518 Underlying: Common Stock · 29.1556 shares Expires not disclosed F1 · security: Each share of phantom stock is the economic equivalent of one share of Gilead common stock. F2 · shares: Phantom shares accrued under dividend equivalent rights, which are settled in shares and distributed with the phantom stock units to which they relate. F3 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. F3 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. Read SEC document |
| July 07, 2021 Filed Jul 9, 2021 14:31 UTC | NEW RITE AID, LLC RAD · Entity 87704 | GrantCommon Stock | 10,617 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-046126 · doc4.xml · nonDerivative · entry 1 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,943 F1 · shares: Grant of restricted stock exempt from Section 16(b) under Rule 16b-(3)(d). Read SEC document |
| June 29, 2021 Filed Jul 2, 2021 01:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantPhantom Stock · Derivative | 30.1326 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-021092 · form4.xml · derivative · entry 1 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,913.0962 Underlying: Common Stock · 30.1326 shares Expires not disclosed F1 · security: Each share of phantom stock is the economic equivalent of one share of Gilead common stock. F2 · shares: Phantom shares accrued under dividend equivalent rights, which are settled in shares and distributed with the phantom stock units to which they relate. F3 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. F3 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. Read SEC document |
| May 12, 2021 Filed May 14, 2021 20:04 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 14,665 | $0.00 Strike: $67.45 | $0.00 |
DisclosureSEC source: 0001127602-21-016797 · form4.xml · derivative · entry 2 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,665 Underlying: Common Stock · 14,665 shares Expires 2031-05-12 F3 · derivative.exercise_date: 25% of the shares subject to the option vest on each three-month anniversary from May 12, 2021 such that 100% of the shares subject to the option will be fully vested and exercisable upon the earlier of May 12, 2022 or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 12, 2021 Filed May 14, 2021 20:04 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Unit · Derivative | 2,223 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-016797 · form4.xml · derivative · entry 1 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,053 Underlying: Common Stock · 2,223 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units will vest on the earlier of May 12, 2022 or the day immediately preceding the next regular annual stockholders meeting. F2 · derivative.expiration_date: 100% of the restricted stock units will vest on the earlier of May 12, 2022 or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 03, 2021 Filed May 4, 2021 21:52 UTC | Medtronic plc MDT · Entity 2888 | GrantOrdinary Shares | 820 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-015324 · form4.xml · nonDerivative · entry 1 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 820 F1 · kind: This restricted stock unit award will vest on the one year anniversary of the grant date. Read SEC document |
| March 30, 2021 Filed Mar 31, 2021 23:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantPhantom Stock · Derivative | 30.9153 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-012442 · form4.xml · derivative · entry 1 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,882.9636 Underlying: Common Stock · 30.9153 shares Expires not disclosed F1 · security: Each share of phantom stock is the economic equivalent of one share of Gilead common stock. F2 · shares: Phantom shares accrued under dividend equivalent rights, which are settled in shares and distributed with the phantom stock units to which they relate. F3 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. F3 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. Read SEC document |
| January 22, 2021 Filed Jan 25, 2021 18:55 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 20,282 | $0.00 Strike: $20.65 | $0.00 |
DisclosureSEC source: 0001127602-21-002420 · form4.xml · derivative · entry 2 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,282 shares Expires 2021-05-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options vested quarterly over one year and were fully vested on May 12, 2012. Read SEC document |
| January 22, 2021 Filed Jan 25, 2021 18:55 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 20,282 | $20.65 | $418,721.89 |
DisclosureSEC source: 0001127602-21-002420 · form4.xml · nonDerivative · entry 1 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,203 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 30, 2020 Filed Jan 4, 2021 18:21 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantPhantom Stock · Derivative | 33.8286 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-000082 · form4.xml · derivative · entry 1 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,852.0483 Underlying: Common Stock · 33.8286 shares Expires not disclosed F1 · security: Each share of phantom stock is the economic equivalent of one share of Gilead common stock. F2 · shares: Phantom shares accrued under dividend equivalent rights, which are settled in shares and distributed with the phantom stock units to which they relate. F3 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. F3 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. Read SEC document |
| November 23, 2020 Filed Dec 29, 2020 20:06 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GiftCommon Stock | 21,720 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-032439 · form4.xml · nonDerivative · entry 1 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,921 F1 · kind: Reflects the gift of common stock to a charitable donor advised fund. Read SEC document |
| September 29, 2020 Filed Oct 1, 2020 21:07 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantPhantom Stock · Derivative | 30.5255 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-026041 · form4.xml · derivative · entry 1 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,818.2197 Underlying: Common Stock · 30.5255 shares Expires not disclosed F1 · security: Each share of phantom stock is the economic equivalent of one share of Gilead common stock. F2 · shares: Phantom shares accrued under dividend equivalent rights, which are settled in shares and distributed with the phantom stock units to which they relate. F3 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. F3 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. Read SEC document |
| July 08, 2020 Filed Jul 9, 2020 14:38 UTC | NEW RITE AID, LLC RAD · Entity 87704 | GrantCommon Stock | 6,682 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-041921 · doc4.xml · nonDerivative · entry 1 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,326 F1 · security: Grant of restricted stock exempt from Section 16(b) under Rule 16b-(3)(d). Read SEC document |
| June 29, 2020 Filed Jul 1, 2020 20:55 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantPhantom Stock · Derivative | 25.1945 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-020665 · form4.xml · derivative · entry 1 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,787.6942 Underlying: Common Stock · 25.1945 shares Expires not disclosed F1 · security: Each share of phantom stock is the economic equivalent of one share of Gilead common stock. F2 · shares: Phantom shares accrued under dividend equivalent rights, which are settled in shares and distributed with the phantom stock units to which they relate. F3 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. F3 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. Read SEC document |
| May 06, 2020 Filed May 8, 2020 00:20 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 7,886 | $0.00 Strike: $77.47 | $0.00 |
DisclosureSEC source: 0001127602-20-015840 · form4.xml · derivative · entry 4 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,886 Underlying: Common Stock · 7,886 shares Expires 2030-05-06 F4 · derivative.exercise_date: 25% of the shares subject to the option vest on each three-month anniversary from May 6, 2020 such that 100% of the shares subject to the option will be fully vested and exercisable upon the earlier of May 6, 2021 or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 06, 2020 Filed May 8, 2020 00:20 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Unit · Derivative | 1,936 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-015840 · form4.xml · derivative · entry 3 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,830 Underlying: Common Stock · 1,936 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: 100% of the restricted stock units will vest upon the earlier of May 6, 2021 or the day immediately preceding the next regular annual stockholders meeting. F3 · derivative.expiration_date: 100% of the restricted stock units will vest upon the earlier of May 6, 2021 or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 05, 2020 Filed May 8, 2020 00:20 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 2,270 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-015840 · form4.xml · derivative · entry 2 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,894 Underlying: Common Stock · 2,270 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units vested May 5, 2020. F2 · derivative.expiration_date: 100% of the restricted stock units vested May 5, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.